Core Viewpoint - A class action lawsuit has been filed against Fly-E Group, Inc. for misleading investors regarding its revenue outlook and sales performance during the class period from July 15, 2025, to August 14, 2025 [6]. Allegation Details - The lawsuit claims that Fly-E's management created a false impression of reliable revenue projections and demand for its electric vehicle (EV) products, while downplaying risks associated with lithium batteries and supply chain issues [6]. - A significant 32% decrease in net revenue was reported, attributed to a decline in total units sold due to customer hesitance linked to lithium battery explosion incidents [6]. Financial Impact - Following the SEC filing on August 14, 2025, Fly-E's stock price plummeted from $7.76 per share to $1.00 per share on August 15, 2025, marking an 87% decline in just one day [6].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended to treat Duchenne muscular dystrophy [1][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing gene therapies, specifically ELEVIDYS for Duchenne muscular dystrophy [3]. Allegations - The lawsuit claims that Sarepta made materially false and misleading statements about ELEVIDYS, leading investors to believe it was a safe therapy with no hindrances to broader application approval [3]. - Specific allegations include: - ELEVIDYS posed significant safety risks to patients [3]. - Trial protocols failed to detect severe side effects [3]. - Adverse events from ELEVIDYS treatment led to a halt in recruitment and dosing, attracting regulatory scrutiny [3]. - Positive statements made by the company lacked a reasonable basis due to undisclosed material adverse facts [3]. Stock Price Impact - Following a safety update on March 18, 2025, where a patient died after treatment with ELEVIDYS, Sarepta's stock price fell by $27.81 (27.44%) to close at $73.54 [4]. - On April 4, 2025, after the company disclosed regulatory requests for a review of the death, the stock price dropped by $4.18 (7.13%) to close at $54.43 [4]. - A second patient death reported on June 15, 2025, caused the stock to plummet by $15.24 (42.12%) to close at $20.91 [4]. - Following an FDA Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks, the stock fell by $1.52 (8.01%) to close at $17.46 [4].